All In Biotech

Drug Trial Radar · NCT00564941

Evaluating the Efficacy of Deferasirox in Transfusion Dependent Chronic Anaemias (Myelodysplastic Syndrome, Beta-thalassaemia Patients) With Chronic Iron Overload

Last checked: Nov 20, 2026Latest source record: Feb 24, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

309

Planned (sponsor's estimate)

Start

Dec 2007

Primary completion

Jul 2011

Study completion Jul 2011

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Nov 29, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the safety and efficacy of deferasirox in transfusion dependent Myelodysplastic Syndrome, Beta-thalassaemia major patients with chronic iron overload

Conditions

  • Myelodysplastic Syndromes
  • Beta-Thalassemia

Interventions

  • deferasiroxDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. This study will evaluate the safety and efficacy of deferasirox in transfusion dependent Myelodysplastic Syndrome, Beta-thalassaemia major patients with chronic iron overloadTime frame: monthly during the therapy and at the end of the treatment (aftr 9 months therapy)

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Budapest, Hungary

  • Novartis Investigative Site

    Debrecen, Hungary

  • Novartis Investigative Site

    Pécs, Hungary

  • Novartis Investigative Site

    Szeged, Hungary

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.